We are driving innovation in our algorithms, emphasizing automation, personalization and simplification, all intended to continue to improve therapeutic outcomes and provide a positive patient experience characterized
by simplicity and ease of use. Examples of our efforts to provide enhanced personalization include alternative targets, settings optimizations and enhanced exercise options. Examples of our efforts to provide greater ease of use include adaptations,
smarter alerts and new signal integrations. In addition, we anticipate pursuing the initiation and design of clinical research to support potential expanded Control-IQ indications for people with type 1 ages 2 to 5 years old, as well as people living
with type 2 diabetes. We are also researching the use of different insulins with our Control-IQ technology, including ultra-rapid insulins, concentrated insulins, and generic insulins.
Our mobile app provides users with a convenient and discreet data display and alerts on their iOS and Android phones, and functions as a pipeline for getting pump data to the cloud. In the 4th quarter of 2020, we submitted
a regulatory filing to the FDA for a mobile bolus delivery feature that will allow t:slim X2 users to control a bolus of insulin using our app. Subject to regulatory review and approval, in the future this app is also planned to include additional
pump control features, such as full operation of our Mobi pump.
Building a robust ecosystem and portfolio around our flagship insulin pumps requires product development efforts to integrate, add and enhance complimentary system components.
Dexcom CGM: In November 2020, we entered into an agreement with Dexcom to extend our current collaboration to include integration with their future G7 CGM technology. Following integrated product development work, and required regulatory clearances or
approvals, this will be the fourth generation of Dexcom CGM that we intend to integrate with our devices.
Abbott CGM: In June 2020, we announced an agreement with Abbott Laboratories (Abbott), to develop and commercialize integrated diabetes solutions that combine Abbott’s CGM technology with our insulin delivery systems. Following the completion of
our integrated product development work, and after obtaining required regulatory clearances or approvals, we intend to focus our initial commercial activities on integrated products in the U.S. and Canada, with additional geographies considered in